NVSNovartis PharmaceuticalsFinished
Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2
Metastatic Pancreatic Ductal Adenocarcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 511 (final count)
- Started
- Sep 30, 2021
- Main results expected
- Aug 13, 2024
- Fully finished
- Aug 13, 2024
- Results posted
- May 19, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Safety run-in Part: Percentage of Participants With Dose Limiting Toxicities (DLTs) During the First Cycle (4 Weeks) of Treatment.
Measured over: Up to 4 weeks
Randomized Part: Overall Survival (OS)
Measured over: From randomization up to death, assessed up to approximately 34 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04935359 · record last updated 2026-05-19 · checked 2026-11-09 15:47 UTC